Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5117]
News [14821]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Monoclonal antibodies in multiple myeloma
Dr Phillippe Moreau - University Hospital of Nantes, Nantes, France
Monoclonal antibodies in multiple myeloma ( Dr Phillippe Moreau - University Hospital of Nantes, Nantes, France )
1 Nov 2016
Preemptively treating patients most at risk of progression to myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Preemptively treating patients most at risk of progression to myeloma ( Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain )
1 Nov 2016
Drug combos with daratumumab likely to become standard of care in myeloma
Dr Niels Van De Donk - VU University Medical Center, Amsterdam, Holland
Drug combos with daratumumab likely to become standard of care in myeloma ( Dr Niels Van De Donk - VU University Medical Center, Amsterdam, Holland )
1 Nov 2016
Overview of the CD38 antibody in multiple myeloma
Dr Torben Plesner - Vejle Hospital, Vejle, Denmark
Overview of the CD38 antibody in multiple myeloma ( Dr Torben Plesner - Vejle Hospital, Vejle, Denmark )
1 Nov 2016
New drugs and combinations in haematological cancers improve complete remission...
Dr Paolo Corradini - University of Milan, Milan, Italy
New drugs and combinations in haematological cancers improve complete remission rates ( Dr Paolo Corradini - University of Milan, Milan, Italy )
1 Nov 2016
Benefits and problems of allogeneic stem cell transplantation as multiple...
Prof Nicolaus Kröger - University Hospital Hamburg, Hamburg, Germany
Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment ( Prof Nicolaus Kröger - University Hospital Hamburg, Hamburg, Germany )
1 Nov 2016
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
What are CDKs?
Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
What are CDKs? ( Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy )
26 Oct 2016
CDK clinical trial results, benefit, side effects and costs
Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy
CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )
26 Oct 2016
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant...
Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
Biomarkers of sensitivity and resistance
Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation